News
EBS
9.50
+4.05%
0.37
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS)
TipRanks · 5d ago
Weekly Report: what happened at EBS last week (0427-0501)?
Weekly Report · 5d ago
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses
Simply Wall St · 05/02 07:45
Emergent BioSolutions Earnings Call Highlights Turnaround Momentum
TipRanks · 05/02 00:45
Emergent (EBS) Q1 2026 Earnings Transcript
The Motley Fool · 05/01 16:26
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance
Seeking Alpha · 05/01 15:12
Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround
TipRanks · 04/30 22:21
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Benzinga · 04/30 21:54
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 04/30 21:06
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Benzinga · 04/30 20:33
Emergent Biosolutions Non-GAAP EPS of $0.21 beats by $0.46, revenue of $156.1M beats by $11.1M
Seeking Alpha · 04/30 20:32
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Benzinga · 04/30 20:32
*Emergent Biosolutions 1Q Net $6.8M >EBS
Dow Jones · 04/30 20:30
*Emergent Biosolutions 1Q EPS 7c >EBS
Dow Jones · 04/30 20:30
*Emergent Biosolutions 1Q Adj EPS 21c >EBS
Dow Jones · 04/30 20:30
Press Release: Emergent BioSolutions Reports First Quarter 2026 Financial Results
Dow Jones · 04/30 20:30
*Emergent Biosolutions 1Q Rev $156.1M >EBS
Dow Jones · 04/30 20:30
Press Release: Emergent BioSolutions Reports -3-
Dow Jones · 04/30 20:30
Emergent Biosolutions: Q1 Earnings Snapshot
Barchart · 04/30 16:20
Emergent BioSolutions receives Singapore regulatory approval for ACAM2000
TipRanks · 04/30 13:58
More
Webull provides a variety of real-time EBS stock news. You can receive the latest news about Emergent Biosolutions Inc through multiple platforms. This information may help you make smarter investment decisions.
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.